Logo

ANIX

Anixa Biosciences, Inc.

ANIX

Anixa Biosciences, Inc. • NASDAQ
$4.59 ▼ -1.08% (-0.05)
Market Cap $151.07 M
52w High $4.98
52w Low $2.07
Dividend Yield 0%
P/E -13.5
Volume 87.59K
Outstanding Shares 32.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $2.436M ▼ $0 ▲ 0% $-0.07 ▲ $-2.436M ▲
Q2-2025 $0 $3.003M ▼ $-2.79M ▲ 0% $-0.087 ▲ $-2.994M ▲
Q1-2025 $0 $3.386M ▲ $-3.184M ▼ 0% $-0.099 ▼ $-3.386M ▼
Q4-2024 $0 $3.163M ▼ $-2.883M ▲ 0% $0.3 ▲ $-3.154M ▲
Q3-2024 $0 $3.592M $-3.277M 0% $-0.1 $-3.589M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $16.029M ▲ $17.651M ▲ $2.24M ▲ $16.595M ▲
Q2-2025 $15.597M ▼ $16.977M ▼ $2.071M ▼ $16.068M ▼
Q1-2025 $17.255M ▼ $18.906M ▼ $2.193M ▼ $17.852M ▼
Q4-2024 $19.924M ▼ $21.591M ▼ $2.703M ▲ $19.998M ▼
Q3-2024 $20.745M $22.908M $2.217M $21.771M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.28M ▲ $-1.511M ▼ $-833K ▼ $1.929M ▲ $-415K ▼ $-1.511M ▼
Q2-2025 $-2.813M ▲ $-1.503M ▲ $2.342M ▼ $18K ▲ $857K ▲ $-1.503M ▲
Q1-2025 $-3.213M ▼ $-2.904M ▼ $2.703M ▲ $-17K ▼ $-218K ▼ $-2.904M ▼
Q4-2024 $-2.913M ▲ $-927K ▲ $867K ▼ $106K ▼ $46K ▼ $-927K ▲
Q3-2024 $-3.277M $-2.643M $2.724M $149K $230K $-2.643M

Five-Year Company Overview

Income Statement

Income Statement Anixa looks like a classic early‑stage biotech: almost no recurring revenue and steady losses each year. The loss level has been fairly consistent, which suggests spending is controlled rather than rapidly ramping. The financial story today is not about sales or profits; it is about funding research and clinical trials with the hope of future commercialization rather than current income generation.

Balance Sheet

Balance Sheet The balance sheet is small and simple. The company holds a modest amount of assets, mostly in cash and equivalents, and carries no debt, which lowers financial risk from lenders. It is funded almost entirely by shareholder equity. However, the asset base has inched down over time, reflecting ongoing use of cash to fund operations, so its ability to self‑fund is limited without new capital injections.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, reflecting the cost of running trials and research without offsetting revenue. Free cash flow is also negative, but capital spending needs are minimal, so the main drain is operating costs, not big equipment or facilities. The burn rate appears controlled but persistent, meaning the company will likely remain dependent on external financing, grants, or partnerships to support its programs over time.

Competitive Edge

Competitive Edge Competitively, Anixa is a very small player in a field dominated by much larger oncology and immunotherapy companies. Its edge comes from a differentiated scientific angle: preventative cancer vaccines based on “retired” proteins and a novel T‑cell therapy design for solid tumors. Strong academic partnerships and exclusive licenses to key technologies add some protection and credibility. Still, the company operates in crowded, fast‑moving areas where many better‑funded rivals are pursuing overlapping goals, so success will depend heavily on clear, compelling clinical data and smart partnering.

Innovation and R&D

Innovation and R&D Innovation is the core of Anixa’s story. The company is advancing a preventative breast cancer vaccine with early safety and immune‑response data, a similar vaccine concept for ovarian cancer, and a specialized T‑cell therapy aimed at difficult solid tumors. Additional discovery work is exploring how its vaccine concept could apply to other major cancers. Much of the value here is tied to ideas that are still in early or mid clinical stages, supported partly by grants and collaborations, but none are yet proven in large, late‑stage trials. Scientific potential is high, but so is the uncertainty typical of early biotech R&D.

Summary

Overall, Anixa is a small, clinical‑stage biotech with high scientific ambition and very early‑stage economics. Financially, it has no meaningful revenue, steady but manageable losses, no debt, and a modest, gradually shrinking cash base, implying ongoing reliance on outside funding. Strategically, its differentiated focus on cancer prevention and novel T‑cell approaches, backed by strong partners and patents, offers clear upside if the science works. At the same time, the company faces intense competition, long timelines, clinical and regulatory risk, and significant dependence on future funding and partnerships. The story is centered on trial outcomes and scientific validation rather than current financial performance.

NEWS

November 17, 2025 · 8:15 AM UTC

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Read more

November 12, 2025 · 11:00 AM UTC

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

Read more

November 12, 2025 · 9:00 AM UTC

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Read more

November 10, 2025 · 10:30 AM UTC

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

Read more

November 5, 2025 · 8:55 AM UTC

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Read more